Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

UroGen Pharma Ltd. - Ordinary Shares (NQ:URGN)

10.54 -0.60 (-5.39%)
Streaming Delayed Price Updated: 11:50 AM EDT, May 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about UroGen Pharma Ltd. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 Next >
The Latest Analyst Ratings for UroGen Pharma
Via Benzinga
Following Pre-NDA Meeting with the FDA, UroGen Announces Rolling NDA Submission for UGN-102 to Begin January 2024
From UroGen Pharma Ltd.
Via Business Wire
Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From UroGen Pharma Ltd.
Via Business Wire
Where UroGen Pharma Stands With Analysts
Via Benzinga
UroGen Pharma Ltd. (NASDAQ: URGN) Leading the Way in Friday Trading Based on Percentage Gain
Via Investor Brand Network
UroGen Pharma to Present at Upcoming Investor Conferences
From UroGen Pharma Ltd.
Via Business Wire
Why NICE Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers PhenomeX Inc. (NASDAQ: CELL) shares surged 138.3% to $0.9532. Bruker Corporation and PhenomeX reported a $108 million definitive agreement for Bruker to acquire PhenomeX in an all-cash... 
Via Benzinga
UroGen Pharma Reports Record JELMYTO Quarterly Sales and Recent Corporate Developments
From UroGen Pharma Ltd.
Via Business Wire
UroGen Pharma Ltd. (NASDAQ: URGN) Near the Top of Equities by Percentage Gain on 7/27
Via Investor Brand Network
Recap: UroGen Pharma Q1 Earnings
Via Benzinga
Earnings Scheduled For August 10, 2023
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million. 
Via Benzinga
The Journal of Urology Publishes Peer-Reviewed Article Highlighting UGN-102 Data in Non-Surgical Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
From UroGen Pharma Ltd.
Via Business Wire
UroGen Pharma to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023
From UroGen Pharma Ltd.
Via Business Wire
$10 Trillion Added In Market Cap; 2023’s Best And Worst Through July
The US stock market has now seen an increase in market cap of roughly $10 trillion from its bear market low last October through the end of July 2023. 
Via Talk Markets
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From UroGen Pharma Ltd.
Via Business Wire
Why Shares of UroGen Pharma Jumped Friday
The company released positive top-line results for two studies for a bladder cancer treatment. 
Via The Motley Fool
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About Yet
Investors are on the hunt for undervalued, underfollowed and emerging stocks, and retail traders have countless methods at their disposal to uncover new information. For some, this may be... 
Via Benzinga
Enphase Energy, Sanofi, Ford And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures traded higher this morning on Friday. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Why UroGen Pharma Stock Is Gaining Today?
UroGen Pharma Ltd (NASDAQ: URGN) shares are surging after the company released topline data from its Phase 3 trials ATLAS and ENVISION studying UGN-102 (mitomycin) for intravesical solution in patients... 
Via Benzinga
UroGen Announces $120 Million Private Placement of Ordinary Shares
From UroGen Pharma Ltd.
Via Business Wire
UGN-102, in Development as the Potential First Non-Surgical Therapy for LG-IR-NMIBC, Met Primary Endpoints in Both Phase 3 ATLAS and ENVISION Clinical Trials
From UroGen Pharma Ltd.
Via Business Wire
UroGen Pharma Announces the Appointment of James Robinson to its Board of Directors
From UroGen Pharma Ltd.
Via Business Wire
Retrospective Study Finds JELMYTO® Use Effective Following Partial Ablation or Biopsy in Larger Volume Low-Grade Upper Tract Urothelial Tumors that Impede Kidney Preservation
From UroGen Pharma Ltd.
Via Business Wire
UroGen Pharma to Host UGN-102 Data Event on July 27, 2023
From UroGen Pharma Ltd.
Via Business Wire
Retrospective Study Reveals Lower Stricture Rate and Comparable Oncological Outcomes with Antegrade Administration of JELMYTO® Versus Retrograde Administration
From UroGen Pharma Ltd.
Via Business Wire
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From UroGen Pharma Ltd.
Via Business Wire
UroGen Pharma to Present at Upcoming Investor Conferences
From UroGen Pharma Ltd.
Via Business Wire
Earnings Scheduled For May 11, 2023
Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings for its fourth quarter. • Exela Technologies (NASDAQ:XELA) is expected to report earnings for its... 
Via Benzinga
UroGen Pharma Meets Revenue Goal, Reports First Quarter 2023 Financial Results and Recent Corporate Developments
From UroGen Pharma Ltd.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback